Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer

NCT ID: NCT06196658

Last Updated: 2024-01-09

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-01
• Study Completion Date: 2027-12-31

Brief Summary

This is a early Phase 1 open-label study to explore the safety and possible efficacy of EX02 CAR T cell therapy in the treatment of patients with unresectable and/or metastatic pancreatic/bile duct cancer.

Each participant will undergo leukapheresis after enrolment, receive treatment of the conditioning chemotherapy of cyclophosphamide and fludarabine, and an intra-tumoral injection or intraperitoneal infusion of Ex02 CAR T cells, probably followed by an intravenous infusion of EX02 CAR T cells.

Each participant will proceed through the following study procedures:

• Screening
• Enrollment/Leukapheresis
• Conditioning chemotherapy
• CAR T treatment
• Post-treatment assessment
• Long-term follow-up

Conditions

Pancreatic Cancer; Advanced Biliary Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

anti-EX02 CAR T cells

Group Type: EXPERIMENTAL

anti-EX02 CAR T cells

Intervention Type: DRUG

Conditioning chemotherapy:

• Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before first administration of first time of intravenous or intraperitoneal infusion

Investigational Product:

• Regional administration: Acetaminophen 500mg orally and diphenhydramine 20mg intramuscularly (or other non-steroidal anti-inflammatory drugs and antihistamines) were given in advance on the day of administration (day 0). Intraperitoneal infusion or intra-tumoral injection of anti-EX02 CAR T cells, with dosage and method determined by the investigator

• Intravenous administration: Single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 2 x 106 anti-EX02 CAR T cells/kg, 30 minutes after premedication with oral acetaminophen 500mg and intramuscular diphenhydramine 20mg

Interventions

anti-EX02 CAR T cells

Conditioning chemotherapy:

• Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before first administration of first time of intravenous or intraperitoneal infusion

Investigational Product:

• Regional administration: Acetaminophen 500mg orally and diphenhydramine 20mg intramuscularly (or other non-steroidal anti-inflammatory drugs and antihistamines) were given in advance on the day of administration (day 0). Intraperitoneal infusion or intra-tumoral injection of anti-EX02 CAR T cells, with dosage and method determined by the investigator

• Intravenous administration: Single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 2 x 106 anti-EX02 CAR T cells/kg, 30 minutes after premedication with oral acetaminophen 500mg and intramuscular diphenhydramine 20mg

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 1) Must have a confirmed diagnosis of unresectable or metastatic pancreatic cancer or bile duct cancer 2) Ineligible for, refractory to or relapsed after first or second line of chemotherapy 3) Presence of at least one measurable target lesion according to RECIST v1.1 4) EX02 positive tumor cell membrane (as shown in IHC staining of tumor specimen or in flow cytometry of ascites cells) 5) Male or female, ≥18 years 6) ECOG performance status 0 to 1 7) Expected life expectancy >3 months 8) Negative pregnancy test at screening and prior to initiating lymphodepletion chemotherapy or study drug administration, and willingness to practice birth control for woman with childbearing potential 9) Adequate hematology function indicated by followings (without blood transfusion or administration with growth factors in last four weeks):

1. Neutrophil count ≥ 1.5×10^9/L

2. Hemoglobin ≥ 90g/L

3. Platelet count ≥ 100×10^9/L

4. Lymphocyte count ≥ 0.5×10^9/L 10) Adequate liver, kidney, heart and lung functions at least indicated by:

<!-- -->

1. Creatinine clearance ≥ 60ml/min

2. ALT and AST ≤ 2.5 ULN (≤ 5 ULN when liver is involved)

3. LVEF ≥ 50%; absence of pericardial fluid; no significant abnormality in ECG exam

4. No or only small amount of pleural fluid or ascites; blood oxygen saturation ≥ 95% 11) Voluntary participation in the trial and signing informed consent form

1. Must have a confirmed diagnosis of unresectable or metastatic pancreatic cancer or bile duct cancer

2. Ineligible for, refractory to or relapsed after first or second line of chemotherapy

3. Presence of at least one measurable target lesion according to RECIST v1.1

4. EX02 positive tumor cell membrane (as shown in IHC staining of tumor specimen or in flow cytometry of ascites cells)

5. Male or female, ≥18 years

6. ECOG performance status 0 to 1

7. Expected life expectancy >3 months

8. Negative pregnancy test at screening and prior to initiating lymphodepletion chemotherapy or study drug administration, and willingness to practice birth control for woman with childbearing potential

9. Adequate hematology function indicated by followings (without blood transfusion or administration with growth factors in last four weeks):

1. Neutrophil count ≥ 1.5×10^9/L

2. Hemoglobin ≥ 90g/L

3. Platelet count ≥ 100×10^9/L

4. Lymphocyte count ≥ 0.5×10^9/L

10. Adequate liver, kidney, heart and lung functions at least indicated by:

1. Creatinine clearance ≥ 60ml/min

2. ALT and AST ≤ 2.5 ULN (≤ 5 ULN when liver is involved)

3. LVEF ≥ 50%; absence of pericardial fluid; no significant abnormality in ECG exam

4. No or only small amount of pleural fluid or ascites; blood oxygen saturation ≥ 95%

11. Voluntary participation in the trial and signing informed consent form

Exclusion Criteria

• 28 participants fulfilling the following criteria will be enrolled.

1. Active viral infection including but not limiting hepatitis A, hepatitis B, hepatitis C or HIV

2. History of acquired immunodeficiency syndrome (AIDS)

3. Is pregnant or lactating

4. Unwilling to practice birth control

5. Planned intraperitoneal chemotherapy (such as HIPEC) within 28 days

6. Received systemic immune inhibitors or corticosteroids (prednisone 15mg/day or above equivalent dose) within 2 weeks of the time of initiating conditioning chemotherapy

7. Current involvement of:

1. Active infection which requires treatment with systemic administration

2. Active coagulation disorders or receiving anti-coagulant treatment (except for aspirin)

3. Active hemolytic anemia

4. Significant arrhythmia, or history of myocardial infarction, ventricular tachycardia, or ventricular fibrillation

5. Active obstructive or constrictive lung disease

6. Active autoimmune disease such as rheumatoid arthritis or immunodeficiency disease

7. Active CNS metastases or cerebrospinal malignancy

8. Uncontrolled diseases including disorders of cardiovascular, respiratory, renal, gastrointestinal, urogenital or immune systems

8. Active second malignancy in addition to the studied one, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma

9. History of hypersensitivity to any drugs planning to be used in this study

10. History of treatment with any genetically modified T cell therapy (including CAR T cells and TCR T cells)

11. Any conditions that investigator consider as ineligibility of participation

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Zeno Therapeutics Pte. Ltd

UNKNOWN

Sponsor Role: collaborator

Zhang Xiaofeng,MD

OTHER

Sponsor Role: lead

Responsible Party

Zhang Xiaofeng,MD

chief physician

Responsibility Role: SPONSOR_INVESTIGATOR

Central Contacts

Xiaofeng Zhang

Role: CONTACT

zxf837@tom.com

057156005600

Xiaofeng Zhang

Role: CONTACT

057156005600

Other Identifiers

20231226

Identifier Type: -

Identifier Source: org_study_id